stockrow
Friday 6 November 2026
Export RPID’s income statement to Excel — free account
Rapid Micro Biosystems, Inc.
RPID Healthcare Medical Devices
Rapid Micro Biosystems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.6 million, up 19.7% from fiscal 2024.
- Revenue
- +10.9%
- EPS
- 0.00%
- Free cash flow
- −24.0%
Quarter to June 2026, against a year earlier
0.64
0.02
+3.23%
Follow RPID
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.92 | 3.86 | 3.00 | 2.38 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(16.59) | (39.92) | (6.85) | (6.58) | |
P/B ratio |
3.39 | 3.90 | 5.06 | 4.71 | |
Price to Tangible BV |
3.39 | 3.90 | 5.06 | 4.71 | |
EV/Sales |
4.18 | 3.28 | 2.89 | 2.36 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.39) | (3.55) | (2.68) | (2.07) | |
EV/FCF |
(3.31) | (3.45) | (2.61) | (2.06) | |
Quick Ratio |
2.82 | 2.24 | 1.53 | 1.39 | |
Current Ratio |
4.23 | 3.31 | 2.57 | 2.55 | |
Net Debt/EBITDA |
2.12 | 1.70 | 0.30 | 0.05 | |
Debt/Assets |
22.31% | 25.25% | 30.55% | 32.74% | |
Debt/Equity |
0.42 | 0.57 | 0.93 | 1.08 | |
Asset Turnover |
0.32 | 0.39 | 0.47 | 0.52 | |
Operating CF/Net income |
0.79 | 0.26 | 1.05 | 0.98 | |
Capex/Depreciation |
(0.09) | (0.12) | (0.50) | 0.29 | |
Interest Coverage |
(28.94) | (18.14) | (21.68) | (19.07) | |
Research and Development Expense of Revenue |
45.02% | 28.54% | 41.98% | 41.37% | |
Selling, General and Administrative Expense of Revenue |
108.94% | 76.79% | 135.77% | 126.67% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
14.62% | 5.56% | 15.28% | 16.40% | |
Graham Net Nets |
0.20 | 0.15 | 0.07 | 0.07 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(30.24%) | (36.90%) | (49.34%) | (64.74%) | |
Free Cash Flow Yield |
(25.69%) | (24.63%) | (36.83%) | (48.29%) | |
Revenue per Share |
0.17 | 0.25 | 0.18 | 0.17 | |
Operating CF per Share |
(0.20) | (0.07) | (0.33) | (0.26) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.20) | (0.07) | (0.34) | (0.26) | |
Cash per Share |
0.92 | 0.86 | 0.51 | 0.41 | |
Shareholders Equity per Share |
0.99 | 0.74 | 0.45 | 0.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.99 | 0.74 | 0.45 | 0.37 | |
Free Cash Flow |
(9.12) | (3.34) | (15.45) | (12.48) | |
Working Capital |
53.40 | 42.68 | 30.11 | 28.11 | |
Capital Expenditures |
(0.07) | (0.09) | (0.39) | 0.22 | |
Net Current Asset Value |
29.88 | 19.52 | 7.26 | 5.56 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.05 | (0.03) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.59 | 5.33 | 5.44 | 5.78 | |
Average Payables |
2.96 | 3.34 | 3.65 | 4.26 | |
Average Inventory |
21.16 | 18.90 | 19.08 | 19.74 | |
Average Assets |
95.13 | 86.51 | 73.90 | 67.02 | |
Average Common Equity |
64.35 | 54.28 | 42.94 | 36.15 |
Columns are period end dates · fundamentals updated 26 Oct 2026